<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561169</url>
  </required_header>
  <id_info>
    <org_study_id>Oseltamivir - 2015</org_study_id>
    <nct_id>NCT02561169</nct_id>
  </id_info>
  <brief_title>A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza</brief_title>
  <official_title>A Randomized Controlled Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre, randomized, placebo controlled, trial. Participants will be patients either
      ≥65 years or with one or more high risk conditions presenting to one of four academic
      emergency departments in Edmonton or Calgary with influenza-like illness. The investigators
      will test for influenza using a point-of-care rapid test and if positive for influenza
      participants will be randomized to oseltamivir or placebo and followed prospectively. The
      primary outcome will be hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will test for influenza using a point-of-care rapid test and if positive
      for influenza participants will be randomized to oseltamivir or placebo and followed
      prospectively. The primary outcome will firstly be defined as a non-elective admission to
      hospital, in contrast to return visits to the emergency department where admission does not
      take place, which will be classified separately. However, a prolonged stay in the emergency
      department (&gt; 24 hours) will also be considered to be hospitalization. Hospitalizations, as
      well as all other outcomes, will be counted up to 28 days following randomization. Secondary
      outcomes will be lower respiratory tract infection, pneumonia, antimicrobial prescriptions,
      acute sinusitis, visits to medical providers and work related absenteeism for up to 28 days
      following randomization will be captured as secondary outcomes during the follow up.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-elective Hospitalizations (number of hospitalizations)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of non-elective hospitalization (days)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower respiratory tract infection (LRTI), (number of LRTIs)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia (number of episodes of pneumonia)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Sinusitis (number of episodes of acute sinusitis)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New antimicrobial prescription (number of antimicrobial prescriptions)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical visits for acute respiratory illness (number of medical visits)</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (number of adverse events)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to intensive or critical care unit (number of admissions)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in intensive or critical care unit (days)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for mechanical ventilation (number of mechanical ventilation)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation (days)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">940</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance &lt; 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.</description>
    <arm_group_label>Oseltamivir</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance &lt; 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcium Carbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient at the University of Alberta Hospital, the Northeast Community Centre,
             Foothills Medical Centre, Rockyview General Hospital emergency departments

          -  ≥ 18 years of age

          -  ≥ 65 years of age OR chronic cardiac or pulmonary disorders (including
             bronchopulmonary dysplasia, cystic fibrosis, and asthma) , diabetes mellitus and
             other metabolic diseases, cancer, immunodeficiency, immunosuppression (due to
             underlying disease and/or therapy), renal disease, anemia, and hemoglobinopathy, any
             condition that can compromise respiratory function or the handling of respiratory
             secretions or that can increase the risk of aspiration

          -  Acute respiratory infection (ARI) exhibiting 2 or more symptoms, onset within last 72
             hours

          -  Laboratory confirmation of influenza infection, onset within last 72 hours

        Exclusion Criteria:

          -  Contraindication to oseltamivir (i.e., previous anaphylaxis)

          -  Resident of a nursing home

          -  Canadian Triage and Acuity Scale (CTAS) 1

          -  Blood pressure &lt; 90 mmHg

          -  Respiratory rate &gt;30 breaths per minute

          -  PaO2 less &lt;88%

          -  Confusion

          -  Inability to eat or drink

          -  Radiographic evidence of pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Loeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Loeb, MD</last_name>
    <phone>905 525 9140</phone>
    <phone_ext>26679</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Foothills Medical Centre Emergency Department</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4W4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eddy Lang, MD</last_name>
      <phone>(403) 943-7573</phone>
      <email>Eddy.Lang@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Leigh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eddy Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rockyview General Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eddy Lang, MD</last_name>
      <phone>(403) 943-7573</phone>
      <email>Eddy.Lang@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northeast Community Health Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5A 5E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Rowe, MD</last_name>
      <phone>780-407-6707</phone>
      <email>Brian.Rowe@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Emergency Department</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Rowe, MD</last_name>
      <phone>780-407-6707</phone>
      <email>Brian.Rowe@ualberta.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 24, 2015</lastchanged_date>
  <firstreceived_date>September 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiviral</keyword>
  <keyword>oseltamivir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
